Why Novo Nordisk Stock Just Crashed

Novo Nordisk (NYSE: NVO) saw its stock price drop 8.1% on Monday after the company announced expectations for its stock over the next five and ten years. Investors were not pleased with the outlook. Novo Nordisk stated that it plans to launch more than five multi-blockbuster new drugs between now and 2030, adding over $23 billion in annual sales.

However, this growth target appears modest given the company's current annual sales of nearly $330 billion, implying a sales growth of just 7% over the next decade. Additionally, Novo Nordisk expects annual revenue growth from 2026 through 2030 to be in line with industry peers, with broadly stable operating margins on its sales.

At a price of 10.7 times trailing earnings and a 4.2% dividend yield covering about 40% of its valuation, Novo Nordisk's stock appears underpriced if it can grow earnings by around 6% annually over the next five years. However, analysts currently expect only 2% annual growth from Novo, and management's promises are even less encouraging.

The Motley Fool's Stock Advisor analysts did not include Novo Nordisk in their list of the 10 best stocks for investors to buy now, suggesting the stock may not be a buy.